Wikipedia -WSS

Wikipedia

author：entertainment 2025-10-01 20:13:56 - browse：17

Adam's take main illustration — Molly Ferguson/STAT

The eye disease physician in charge of a committee that flagged a rare but severe side effect involving a newly approved drug from Apellis Pharmaceuticals has financial ties to a competing drugmaker. The conflict raises questions about his supervision of an emerging safety issue for patients and its impact on the financial health of Apellis.

Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic, failed to report consulting fees and stock ownership in Iveric Bio on a financial disclosure form maintained by the American Society of Retina Specialists, or ASRS. Iveric Bio is developing a treatment for geographic atrophy, a common, age-related cause of vision loss and the same indication for which the Apellis drug was approved.

The financial conflict, which was undisclosed until after Kaiser was contacted about it by STAT, is relevant because Kaiser also chairs a committee of the ASRS responsible for monitoring the safety of retina drugs and devices. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving injections of Syfovre, the treatment recently approved and launched by Apellis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Shingles, which affected Dianne Feinstein, is on the rise

hotspot

entertainment

WSS

Listen: Wegovy in the brain & pivotal Alzheimer's data

Medicare to cover more brain scans for Alzheimer’s patients

Covid vaccines: Private market messier than government rollout

STAT Virtual Event: The State of Biosimilars: What to Watch

Custom gene therapy hints at new path for rare disease treatments

STAT Virtual Event: How to Increase Diversity in Clinical Trials

focus

Wikipedia

focus

Sports medicine is finally prioritizing gender equality

Medicare drug price negotiation program allowed for now

Heart attack and stroke risk calculators need revising

Shingles, which affected Dianne Feinstein, is on the rise

State Dept. review finds Biden bears some blame for Afghanistan failures

Menendez indictment could see pharma lose a key ally

The high cost of giving birth even with insurance

As digital health tech proliferates, a new institute aims to cut through hype

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

At Orexo, a ‘turning point’ for everything but digital health

hotspot

Menendez indictment could see pharma lose a key ally

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

WHO recommends dropping component of many flu vaccines

Google and Epic fight stronger regulation of AI in health care

STAT Virtual Event: How to Increase Diversity in Clinical Trials

A public scorecard can help hold safety

hotspot

entertainment

hotspot

explore